PD-L1 by clone SP142 [Presence] in Tissue by Immune stain

PD-L1 by SP142 Tiss Ql ImStn

Definition

This term should be used to report the degree of PD-L1 (CD274) protein expression in tumor cells as determined by immune staining with anti-PD-L1 clone SP142. Patients with certain cancers, such as non small cell lung cancer (NSCLC) or urothelial carcinoma, whose tumors are positive for PD-L1 by SP142, may be eligible for anti-programmed death 1 (PD-1) receptor antibody therapy, which effectively prevents the binding of PD-L1 to PD-1. The percentage of viable tumor cells that show partial or complete PD-L1 membrane staining is reported using [LOINC: 83053-9]. If at least 50% of tumor cells or at least 10% of inflammatory cells stain positive with SP142, the tumor is considered to have high PD-L1 expression, and if 1 to 50% of tumor cells and 1 to 10% of inflammatory cells stain positive, the tumor has low expression. If <1% of both tumor and inflammatory cells stain positive, the tumor is considered to have no PD-L1 expression. This term was created for, but is not limited in use to, the Ventana PD-L1 (SP142) assay, which, as of November 2016, is FDA-approved as a companion diagnostic to assess whether patients with certain cancers are eligible for atezolizumab therapy.

B7 homolog 1; B7-H1; CD274; Cluster of differentiation 274; i; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; PDL1; PD-L1; PD-L1 by SP142; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified